Aquestive therapeutics resubmits new drug application for libervant™ (diazepam) buccal film

Warren, n.j., june 24, 2021 (globe newswire) -- aquestive therapeutics, inc. (nasdaq: aqst), a pharmaceutical company focused on developing and commercializing differentiated products that address patients' unmet needs and solve therapeutic problems, announced today the resubmission of its new drug application (nda) to the u.s. food and drug administration (fda) for libervant™ (diazepam) buccal film for the management of seizure clusters in response to the september 25, 2020 complete response letter (crl) from the fda. the submission included additional statistical modeling and supporting analyses of the existing clinical data based upon the guidance received from the agency.
AQST Ratings Summary
AQST Quant Ranking